Clinical Trial

Phase I Study of XTL6001 Injection in Healthy and Obese Subjects

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated October 3, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter, randomized, double-blind, placebo-controlled Phase I study to evaluate safety, PK and PD of single ascending dose (SAD) and multiple ascending dose (MAD) of XTL6001 injection in healthy and obese adult subjects. SAD study: Includes 5 dose cohorts, with 40 subjects planned for enrollment. MAD study Includes 2 dose cohorts, with 30 subjects planned for enrollment.
Trial Details
NCT Number NCT07205432
Lead Sponsor Shanghai Xitaili Biomedicine Technology co., Ltd.
Conditions Weight Management in Adult Patients With Obesity or Overweight
Enrollment 80 participants
Start Date 2025-06-13
Primary Completion 2026-04 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2025-10-03